Clinical Trials, Conditions, DEA and Pharmaceutical

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. Drug Enforcement Agency (DEA). This means that the medical and scientific communities can now celebrate broader access to research for the production of pharmaceutical products that are safer than smokable or vaporizable cannabis.

Pharmaceutical

Pharmaceutical Research and Development DEA Clinical Trials

DEA Faces Lawsuit For Denying End of Life Patients the Right to Try Psychedelics Therapy

Veriheal

JUNE 29, 2021

In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. The lawsuit came after the DEA denied their application to utilize a synthetic form of psilocybin under the RTT laws. A Push by Patients.

Therapy

Therapy DEA Patients Clinical Trials

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ is confident that their pharmaceutical drugs will bring much needed relief to patients suffering from the debilitating effects of Multiple Sclerosis and Huntington’s Disease.

DEA

DEA Clinical Trials THC Research and Development

DMT Therapy: Coming to a Clinic Near You?

Canna Law Blog

NOVEMBER 27, 2021

So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.” This research—as with psilocybin, MDMA, ketamine, ibogaine etc.—is

Therapy

Therapy Clinical Trials DEA Microdosing

Veterans Try Cannabis To Treat PTSD

SpeedWeed

MARCH 28, 2021

CANNABIS CULTURE – The results are now in after the first-ever legal clinical trial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? It was also unique because it used whole-plant cannabis, rather than single-molecule extracts or synthetic pharmaceutical cannabinoids. .

Clinical Trials

Clinical Trials DEA Treatment THC

MAPS Organization Granted $12.9 Million to Study Cannabis and PTSD •

SpeedWeed

AUGUST 11, 2021

With a goal of determining the “the efficacy of marijuana in treating the medical conditions of United States armed services veterans and preventing veteran suicide.”. We overcame significant regulatory obstacles obstructing cannabis research to conduct the first clinical trial of inhaled cannabis for PTSD ,” said Yazar-Klosinki. .

Clinical Trials

Clinical Trials Research and Development Pharmaceutical DEA

PHILLIPS LYTLE LLP LAUNCHES PSYCHEDELICS & MENTAL HEALTH THERAPIES PRACTICE

Cannabis Law Report

AUGUST 18, 2022

Among the first in the nation, Phillips Lytle’s Psychedelics Practice Team combines expertise in pharmaceutical science, FDA regulations and risk management to serve the legal needs of emerging bio-tech sectors. “We are at the beginning of a revolution in how mental health conditions are medically treated. Tweet this.

Therapy

Therapy Research and Development Pharmaceutical Treatment

Press Release: MAPS Places Fully Validated, Multi-Kilogram Synthesis of MDMA in the Public Domain?

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment.

Clinical Trials

Clinical Trials Research and Development Therapy Media

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval.

Extraction

Extraction Pharmaceutical CBD Epilepsy

The Ketamine Clinic Craze: Legalities and Possibilities

Canna Law Blog

MARCH 4, 2020

From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. So, how does one lawfully open and operate a ketamine clinic for infusion therapy given the foregoing?

Therapy

Therapy Legalization Chronic Pain DEA

New Frontiers in the Law of Psychedelics

Cannabis Law Report

JULY 9, 2021

Further, numerous private companies have begun to research psychedelic therapy and develop new pharmaceutical compounds derived from psychedelic substances. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link]. Drug Enforcement Agency (“DEA”).

Law

Law Therapy Clinical Trials Research and Development

The Ketamine Clinic Craze: Legalities and Possibilities

Canna Law Blog

MARCH 4, 2020

From 2015 to 2018, the number of clinics increased from 60 to 300; that number is undoubtedly higher today. People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. So, how does one lawfully open and operate a ketamine clinic for infusion therapy given the foregoing?

Legalization

Legalization Therapy Chronic Pain DEA

New PTSD study finds cannabis safe, but not as effective as assumed

SpeedWeed

MARCH 18, 2021

Given the topical nature of the current trial and its relevance for public policy on medical cannabis, participants might have been biased to report positive effects regardless of condition. for the production of cannabis used in federally-regulated clinical trials. It tested at only 9% THC. Establishing cannabis as safe.

Clinical Trials

Clinical Trials THC Strains Cannabis

CBD: Everything You Need to Know

CannaMD

AUGUST 8, 2020

Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. CBD Scheduling Rule Change. But the government is clear.

CBD

CBD DEA Research and Development Hemp

What’s the deal with ketamine? Q&A on Special K

The Cannigma

MAY 1, 2023

2 3 As clinical trials around the world proceeded in the late 1960s and 1970s, patients began reporting difficulty tolerating ketamine’s unpleasant hallucinogenic and dissociative properties. Ketamine was approved by the FDA in 1970 and was immediately put to use as an important tool for war medics in the Vietnam War.

Blood Pressure

Blood Pressure Chronic Pain Research and Development Clinical Trials

Veriheal’s Innovation in Cannabis Scholarship 2020 Winners

Veriheal

AUGUST 31, 2020

He was exposed to alternative herbal options during his volunteer work as a Spanish interpreter at migrant clinics, and he became interested in medical cannabis when his mother asked him about CBD oil and cannabis as alternative options for her daily shoulder pain. . School: University of Maryland.

Research and Development

Research and Development Education Agriculture Patients

US Hemp Roundtable: Statement On The Status of Hemp Derived CBD Under Federal Law

Cannabis Law Report

JANUARY 11, 2019

Accordingly, the Drug Enforcement Administration (DEA) no longer has any claim to interfere with the interstate commerce of hemp products, so as long as the THC level is at or below 0.3%. While the DEA is now officially out of the hemp regulation business, the U.S. The FDA’s position on CBD is unsettled and unsupported by law.

Hemp

Hemp CBD Law Seed-To-Sale

Medical Cannabis Brief

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

DEA Faces Lawsuit For Denying End of Life Patients the Right to Try Psychedelics Therapy

Trending Sources

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

DMT Therapy: Coming to a Clinic Near You?

Veterans Try Cannabis To Treat PTSD

MAPS Organization Granted $12.9 Million to Study Cannabis and PTSD •

PHILLIPS LYTLE LLP LAUNCHES PSYCHEDELICS & MENTAL HEALTH THERAPIES PRACTICE

Press Release: MAPS Places Fully Validated, Multi-Kilogram Synthesis of MDMA in the Public Domain?

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

The Ketamine Clinic Craze: Legalities and Possibilities

New Frontiers in the Law of Psychedelics

The Ketamine Clinic Craze: Legalities and Possibilities

New PTSD study finds cannabis safe, but not as effective as assumed

CBD: Everything You Need to Know

What’s the deal with ketamine? Q&A on Special K

Veriheal’s Innovation in Cannabis Scholarship 2020 Winners

US Hemp Roundtable: Statement On The Status of Hemp Derived CBD Under Federal Law

Stay Connected